Risk Factors for Drug Allergies in Pediatric Palliative Care Patients

Öz

Background / aim: Children receiving pediatric palliative care constitute a medically fragile population. Despite this vulnerable clinical profile, data on drug allergy in pediatric palliative care remain scarce. This study aimed to determine the frequency, clinical characteristics, and associated factors of clinically defined drug allergy in children hospitalized in a tertiary pediatric palliative care center. Methods: This retrospective observational study included all children hospitalized in a tertiary pediatric palliative care center. Drug allergy was clinically defined according to predefined diagnostic criteria, and in vivo and/or in vitro allergy work-up was performed in selected patients. Demographic and clinical characteristics, hospitalization-related variables, and medication burden were compared between patients with and without drug allergy. Results: A total of 281 hospitalized children were included. Clinically defined drug allergy was identified in 26 patients (9.2%). Antimicrobials were the most frequently implicated drug group (57.7%), followed by antiepileptic drugs (11.5%) and non-steroidal anti-inflammatory drugs (7.7%). Most reactions were immediate (21/26), whereas 5 were non-immediate. One patient developed ranitidine-associated anaphylaxis, and one developed oxybutynin-associated DRESS. In multivariate analysis, older age (OR 1.168; 95% CI 1.036-1.316; p=0.011), longer hospital stay (OR 1.032; 95% CI 1.014-1.050; p<0.001), and a higher number of medications (OR 1.656; 95% CI 1.254-2.189; p<0.001) remained independently associated with drug allergy. Conclusions: Clinically defined drug allergy was not uncommon among hospitalized children receiving pediatric palliative care. Antimicrobials were the leading culprit drugs, while antiepileptic drugs also represented a notable contributor, likely reflecting the high neurological disease burden of this population. Greater medication exposure and prolonged hospitalization were the strongest correlates of drug allergy.

Anahtar Kelimeler

• Pediatrics
• Palliative Care
• Drug Hypersensitivity
• Drug Allergy
• Polypharmacy

Etik Beyan

The study included pediatric patients hospitalized between November 2018 and March 2022. The study protocol was approved by İzmir Dr. Behçet Uz Children’s Diseases and Surgery Training and Research Hospital Hospital institutional local ethics committee (Approval date: 11.08.2022, approval number: GOA-722).

Çocuk Palyatif Bakım Hastalarında ilaç Alerjileri için risk faktörleri

Öz

Amaç: Pediatrik palyatif bakım alan çocuklar; tıbbi açıdan hassas bir popülasyonu oluşturmaktadır. Bu hassas profile rağmen, pediatrik palyatif bakımda ilaç alerjisine ilişkin veriler sınırlıdır. Bu çalışmanın amacı, üçüncü basamak pediatrik palyatif bakım merkezine yatırılan çocuklarda klinik olarak tanımlanmış ilaç alerjisinin sıklığını, klinik özelliklerini ve ilişkili risk faktörlerini belirlemektir. Yöntemler: Bu retrospektif gözlemsel çalışmaya, üçüncü basamak pediatrik palyatif bakım merkezine yatırılan tüm çocuklar dahil edildi. İlaç alerjisi, önceden tanımlanmış tanısal kriterlere göre klinik olarak tanımlandı ve seçilmiş hastalarda in vivo ve/veya in vitro alerjik değerlendirme yapıldı. İlaç alerjisi olan ve olmayan hastalar arasında demografik ve klinik özellikler, hastaneye yatışla ilişkili değişkenler ve ilaç yükü karşılaştırıldı. Bulgular: Toplam 281 çocuk çalışmaya dahil edildi. Klinik olarak tanımlanmış ilaç alerjisi 26 hastada (%9,2) saptandı. En sık suçlanan ilaç grubu antimikrobiyallerdi (%57,7); bunu antiepileptik ilaçlar (%11,5) ve nonsteroid antiinflamatuvar ilaçlar (%7,7) izledi. Reaksiyonların çoğu erken tipteydi (21/26), 5’i ise geç tipteydi. Bir hastada ranitidin ile ilişkili anafilaksi, bir hastada ise oksibutinin ile ilişkili DRESS gelişti. Çok değişkenli analizde ileri yaş (OR 1,168; %95 GA 1,036-1,316; p=0,011), daha uzun hastanede kalış süresi (OR 1,032; %95 GA 1,014-1,050; p<0,001) ve daha fazla sayıda ilaç kullanımı (OR 1,656; %95 GA 1,254-2,189; p<0,001) ilaç alerjisi ile bağımsız olarak ilişkili bulundu. Sonuç: Pediatrik palyatif bakım hastalarında klinik olarak tanımlanmış ilaç alerjisi nadir değildir. Antimikrobiyaller en sık suçlanan ilaç grubu iken, antiepileptik ilaçlar da bu popülasyondaki yüksek nörolojik hastalık yükünü yansıtır biçimde dikkate değer bir katkı sağlamıştır. Daha fazla ilaç maruziyeti ve uzun süreli hastanede kalış, ilaç alerjisiyle en güçlü ilişkili faktörler olmuştur.

Anahtar Kelimeler

• Pediatri
• Palyatif Bakım
• İlaç Aşırı Duyarlılığı
• İlaç Alerjisi
• Çoklu İlaç Kullanımı

Kaynakça

1. 1.Zanin A, Baratiri F, Roverato B, et al.Polypharmacy in children with medical complexity:a cross-sectional study in a pediatric palliative carecenter. Children. 2024; 11(7): 821.
2. 2. Mengato D, Zanin A, Baratiri F, et al. Polypharmacy in Pediatric Palliative Care: Exploring DiscrepanciesBetween Physicians and Pharmacists. Children(Basel). 2025; 12(2): 124.
3. 3.Berges-Gimeno MP, Alvarez-Cuesta E,Atanaskovic-Markovic M, et al. Drughypersensitivity reactions in children in clinicalpractice: A WAO Statement. World Allergy Organ J.2025; 18(9): 101087.
4. 4.Cravidi C, Caimmi S, De Filippo M, et al. DrugAllergy in children: focus on beta-lactams andNSAIDs. Acta Biomed. 2020; 91(11-S): e2020008.
5. 5.Gomes ER, Brockow K, Kuyucu S, et al. Drughypersensitivity in children: report from thepediatric task force of the EAACI Drug AllergyInterest Group. Allergy. 2016; 71(2): 149-61.
6. 6.Silva DC, Araujo OR, Arduini RG, et al. Adversedrug events in a paediatric intensive care unit: aprospective cohort. BMJ Open. 2013; 3(2): e001868.
7. 7.Moral L, Toral T, Muñoz C, et al. Direct oralchallenge for immediate and non-immediate beta-lactam allergy in children: a real-world multicenterstudy. Pediatr Allergy Immunol. 2024; 35(3):e14096.
8. 8.Alghamdi AA, Keers RN, Sutherland A, et al.Incidence and nature of adverse drug events inpaediatric intensive care units: A prospectivemulticentre study. Br J Clin Pharmacol. 2022; 88(5):2213-22.

9. 9.Sacerdoti G, Vozza A, Ruocco V. Identifying skinreactions to drugs. Int J Dermatol. 1993; 32(7): 469-79.
10. 10.Özmen S, Şahin M, Yöney A, et al. Cutaneous drugeruptions in children; single centre experience. TurkArch Pediatr 2011; 46: 62-6.
11. 11.Büyük Yaytokgil Ş, Vezir E. Characteristics ofDrug Hypersensitivity Reactions in Children: ARetrospective Analysis in an Allergy OutpatientClinic. Turkish J Pediatr Dis 2024; 18: 247-52.
12. 12.Büyük Yaytokgil Ş, Selmanoglu A, Kulhas Celik I,et al. Evaluation of the frequency and characteristicsof drug hypersensitivity reactions in hospitalizedchildren: Real life-cohort study. World Allergy Organ J.2024; 17(4): 100893.
13. 13.Broyles AD, Banerji A, Castells M. PracticalGuidance for the Evaluation and Management ofDrug Hypersensitivity: General Concepts. J AllergyClin Immunol Pract. 2020; 8(9S): S3-S15.
14. 14.Shirzad-Yazdi N, Taheri S, Vazin A, et al. Drug-related problems among pediatric intensive careunits: prevalence, risk factors, and clinical pharmacists' interventions. BMC Pediatr. 2024; 24(1): 714.
15. 15.Felix MMR, Kuschnir FC, Boechat JL, Castells M.Recent findings on drug hypersensitivity in children.Front Allergy. 2024; 5: 1330517.
16. 16.Mori F, Blanca-Lopez N, Caubet JC, et al. Delayedhypersensitivity to antiepileptic drugs in children.Curr Pharm Des. 2010; 16(26): 2882-6.
17. 17.Nohavicka L, Harrop E, Mellor C, Vawda H,Villanueva G. Management of seizures in childrenand young people in the palliative care setting.Bristol: Association for Paediatric PalliativeMedicine; 2023: 7-9.
18. 18.Mori F, Saretta F, Riscassi S, et al. Risk factors fordrug hypersensitivity reactions in children. Ital JPediatr. 2024; 50(1): 127.
19. 19.Çevik S, Altaş U, Alkaya H, Özkars MY.Retrospective evaluation of patients undergoingdrug provocation tests. Dicle Medical Journal. 2025;52(1): 63-70.
20. 20.Toni E, Ayatollahi H, Abbaszadeh R, FotuhiSiahpirani A. Risk Factors Associated With Drug-Related Side Effects in Children: A Scoping Review.Glob Pediatr Health. 2024; 11:2333794X241273171.
21. 21.Amarri S, Ottaviani A, Campagna A, De Panfilis L;Emilia Romagna paediatric palliative care workinggroup. Children with medical complexity andpaediatric palliative care: a retrospective cross-sectional survey of prevalence and needs. Ital JPediatr. 2021; 47(1): 110.
22. 22.Arasi S, Barni S, Caminiti L, et al. Latex Allergy inChildren. J Clin Med. 2023; 13(1): 124.
23. 23.Ausili E, Tabacco F, Focarelli B, et al. Prevalenceof latex allergy in spina bifida: genetic andenvironmental risk factors. Eur Rev Med PharmacolSci. 2007; 11(3): 149-53.